Health News

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences’ proprietary PhAROS drug discovery platform.

LAS VEGAS – October 27, 2022 – (Newswire.com)

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines’ ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled “The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals,” Dr. Small-Howard will introduce PhAROS™, Gb Sciences’ proprietary AI-enabled drug discovery platform. Dr. Small-Howard will also present case studies establishing how the company has utilized PhAROS™ to combine information from plant-based medical systems with modern in silico drug discovery tools that identify novel plant-inspired therapies for treating critical medical needs. 

“Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools. We are leveraging our AI-enabled platform with its unique database of known traditional medical plant species to uncover novel minimum essential mixtures of ingredients with therapeutic benefits and reduced side effect profiles. Our AI-enabled drug discovery platform also reduces the time and money needed to get results,” said Dr. Andrea Small-Howard. “With current drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain or novel options for patients suffering with anxiety and depression, we are establishing the value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures.”

Dr. Andrea Small-Howard of Gb Sciences was recently featured on MarketScale’s “IDC with Kevin Stevenson” podcast in an episode entitled “Bringing Medicines to Market Faster Through Analytics and Machine Learning” where she discussed the need for digital transformation in the biopharma industry and the fact that Gb Sciences is ahead of the majority of the industry through the development and use of their PhAROS™ platform for drug discovery. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

TODAY: Gb Sciences’ President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

PHILADELPHIA – October 27, 2022 – (Newswire.com)

 This contract follows Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.

Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry’s gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.

“The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said Jeremy Stackawitz, CEO of Senzo.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.

Contact Information:

Alex Mohacs

Sales & Marketing

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo’s Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

PHILADELPHIA – October 27, 2022 – (Newswire.com)

 This contract follows Senzo’s recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.

Senzo’s core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry’s gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.

“The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it’s that simple. BARDA’s support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market,” said Jeremy Stackawitz, CEO of Senzo.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.

Contact Information:

Alex Mohacs

Sales & Marketing

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

NEW YORK – October 26, 2022 – (Newswire.com)

Akelos Inc. has been …

LA VERNE, Calif. – October 26, 2022 – (Newswire.com)

AARDVARK and Sky-Hero are pleased to announce the release of the world’s first National Defense Authorization Act (NDAA)-compliant interior use tactical sUAS, LOKI Mk2US. The Mk2US is built to comply with the rigorous standards set forth in the NDAA and the recent Department of Defense black-listing of certain Chinese-made drone parts and technologies.  

In response, Sky-Hero, the world’s leading manufacturer of interior tactical robotics, redesigned and resourced the LOKI Mk2 to eliminate all of the covered Chinese components and replace them with European or American items.  

Speaking about this new drone, Yves Coppye, CEO of Sky-Hero, stated: 

“We have been asked by many of our top users around the world to ensure that all major components are built by NATO countries. After two years of work, we are pleased to announce that we have reengineered and redesigned these components and located American or European sources for them.”

Jon Becker, AARDVARK’s CEO, echoed this by stating: 

“We are extremely excited to see Sky-Hero release an NDAA-compliant version of LOKI. While there are a number of products on the market that claim to be American, in reality, the large majority of drones are simply built with Chinese-made parts and at best assembled in the U.S. LOKI Mk2US has always been made by NATO allies and now every NDAA-covered component will be too.” 

The LOKI Mk2US will begin shipping in Q1 of 2023. LOKI Mk2 is sold exclusively in North America by AARDVARK. Visit LOKI.AARDVARKTactical.com to learn more.

About AARDVARK: Founded in 1987, AARDVARK is a leading manufacturer, distributor, and system integrator of products to protect tactical operators from Local, State, Federal, and Military Units. AARDVARK is headquartered in La Verne, CA.

About SKY-HERO: Founded in 2013, Sky-Hero is a dynamic, flexible, fast-growing company specializing in drones and robotics and located in Brussels. With a target market in civil security, their clients range from Police Special Forces to International Security companies, mountain rescue teams, and firefighters.

About LOKI-Mk2 – LOKI Mk2 is a rugged, purpose-built sUAS intended to act as a scout for close-quarter, confined space, and indoor missions. LOKI Mk2 requires no internet service, no GPS, no phone or tablet connection, and has no forced software updates, making it mission capable in seconds from virtually anywhere. LOKI Mk2 performs in almost any lighting condition, seamlessly transitioning from sunlight to complete darkness. 

Contact Information:

Brent Doan

Director of Sales

[email protected]

909-451-6105

Related Files
_F8A2177.jpg
loki2_3qtr_top.sitting.rf_img_1235.jpg

Press Release Service
by
Newswire.com

Original Source:

SKY-HERO and AARDVARK Announce World’s First NDAA-Compliant Interior sUAS Platform

Data-Driven Insights Go Beyond Utilization to Assess Market Propensity for Ambulatory Surgery Center Use

PITTSBURGH …

eSource is the agile response to promote continuity of clinical trials even in uncertain times.

CliniOps Recognized in Gartner\u00ae Hype Cycles Fo…

Dr. Hayden Franks and Bailey Pollock, PA Dr. Hayden Franks and Bailey W. Pollock, PA, at Franks Dermatology in Little Rock, Arkansas
LITTLE ROCK, Ark. – …